Please login to the form below
Gilead completes acquisition of MiroBio in $405m cash deal
The UK biotech is a spin-out of Oxford University focused on research into autoimmune diseases
Novo Nordisk to acquire Forma Therapeutics in deal worth $1.1bn
The acquisition will focus on expanding the company’s blood disorders portfolio
Novartis to separate generic drugs division Sandoz to create standalone company
The spin-off will allow shareholders to participate fully in the potential future upside of both companies
Merck and Orna agree on deal worth $3.5bn for RNA technology
The companies will work together to develop proprietary circular RNA technology
Bristol Myers Squibb successfully completes acquisition of Turning Point Therapeutics
The deal offers BMS a pipeline of investigational medicines to expand its oncology portfolio, including repotrectinib
Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
The companies will work together to develop new therapies to re-establish immune tolerance and repair tissue for those with inflammatory bowel diseases
Merck and Cerevance to research novel targets in Alzheimer’s disease
The total value of the deal is expected to be around $1.1bn
Pfizer set to acquire Global Blood Therapeutics in deal worth $5.4bn
The acquisition will help accelerate research into sickle cell disease
AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
The agreement will focus on drug discovery, development and commercialisation of neurological diseases
Health coverage across state lines
Despite a total lack of legislative wins, the new administration has made its presence felt at home and abroad
-
Standing out in a crowdCelltrion Healthcare’s Ho-Ung Kim on pricing, market access and regulatory challenges for successfully developing biosimilars
-
The diseased organisationLike humans, organisations can be afflicted by genetic disorders that hinder performance and threaten survival but these can be understood and cured
-
Amgen acquires ChemoCentryx in $3.7bn cash dealThe agreement includes the acquisition of ChemoCentryx’s autoimmune disease treatment Tavneos
-
Gilead Sciences set to acquire MiroBio in deal worth over $400mThe UK biotech is a spin-out of Oxford University and focuses on research into autoimmune diseases
-
GSK’s ViiV and Medicines Patent Pool agree deal for HIV preventionThe agreement aims to expand access to HIV prevention in the developing world
-
Moderna secures £1.74bn deal to supply US government with updated COVID-19 vaccineThe company will supply 66 million doses of its COVID-19 vaccine booster updated for the Omicron subvariant
-
NewAmsterdam Pharma and Frazier LifeSciences announce merger agreementThe agreement will provide the Dutch biotech with additional resources for its cholesterol-lowering drug candidate
-
Amazon acquires One Medical in $3.9bn cash dealThe merger is the next step in the online retail giant’s expansion into the healthcare sector
-
GSK’s consumer health spin-off Haleon starts trading with £31bn market valuationThe company finalised its demerger of the Consumer Healthcare business group to form the new organisation
-
New hires at Ferring, Flexion and Immunocore The latest movers in pharma
-
New hires at Nanoform, Leo Pharma and CalliditasThe latest movers in pharma and biotech
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMOLatest movers in pharma and biotech
-
New hires at Mundipharma, Sinclair Pharma and Relay TherapeuticsLatest movers in pharma
-
Ipsen hires general manager, Laura Hamill joins Gilead and Orchard expands leadership teamThe latest industry movers
Latest sales appointments
Subscribe to our email news alerts
Featured jobs
- Associate Vice President, Scientific Services, Medical Communica...
-
Highly competitive salary
- Scientific Team Leader, Scientific Services, Medical Communicati...
-
Highly competitive salary
- Commercial Director, Medical Education, UK six figure package
-
Six figure salary
- Business Development Director, Medical Education - exciting new ...
-
Up to £120K base
- Biogen to pay $900m to settle whistleblower’s MS drug kickback lawsuit
- Biogen and Eisai’s lecanemab shows promise in confirmatory Alzheimer’s study
- Amylyx’s Relyvrio receives FDA approval for ALS treatment
- Janssen’s Erleada combination accepted in Scotland for prostate cancer
- Cancer Research UK scientists announce ‘breakthrough’ in understanding of metastasis
- AstraZeneca’s Tezspire receives MHRA approval as add-on treatment for severe asthma
- Medscape Medical Affairs
- Envision Pharma Group appoints Head of Envision Value & Access
- How AI is finally helping rare diseases gain more than just attention
- WHO unveils new initiative to halt spread of invasive malaria vector in Africa
- NHS England launches lung cancer awareness drive in country’s cancer hotspots
- InflaRx seeks FDA authorisation for vilobelimab for critically ill COVID-19 patients
- COVID-19 linked to long-term neurologic disorders in new US study
- Pfizer and Sangamo Therapeutics reopen recruitment for haemophilia A gene therapy trial
- WHO unveils new initiative to halt spread of invasive malaria vector in Africa
- EC approves Alexion's Ultomiris as generalised myasthenia gravis treatment
- Lilly’s Retevmo approved by FDA for RET fusion+ advanced/metastatic solid tumours
- Merck bags NICE recommendation for renal cell carcinoma adjuvant treatment
PMHub
KVA
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...
Latest intelligence
- How AI is finally helping rare diseases gain more than just attention
- By Neil Thompson...
- Is communication failing us?
- Compelling people to care in a world oversaturated with news and information...
- Are your field teams ready to excel in the new era?
- A qualitative research approach to help you critically assess post-pandemic learnings and ignite the potential of meaningful interactions with HCPs....
